Full-Time
Scientist – Pharmacometrics
Posted on 9/8/2026
Certara
1,001-5,000 employees
Biosimulation and model-informed drug development platform
No salary listed
Germany
Remote
PharmD, PhD, MD
 Biology & Biotech (1) |
|---|
Get referred to Certara
See people who can refer or advise you
- PhD, MD, or PharmD in Bioengineering, Pharmaceutical Sciences, Pharmacology, Statistics, Applied Mathematics, Engineering, Medicine, or a related field.
- One to five years of industry or consulting experience, which may be combined with academic research, working in research and development, pre-clinical, and clinical environments.
- Expertise in pharmacometrics, clinical pharmacology, pharmacokinetics, or a related discipline in a project team setting.
- Expertise in pharmacokinetic/pharmacodynamic modeling with strong quantitative skills applied to nonlinear, mechanistic, or semi-mechanistic models relating to mechanism of action and specific drug-development questions.
- Proficiency in pharmacokinetic/pharmacodynamic and statistical software, including NONMEM and R.
- Proficiency in population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses, model-based meta-analysis, dose-response and exposure-response analyses, dataset creation, disease modeling, trial simulation, optimal study designs, strategic decision analyses, and economic modeling.
- Independent performance of analysis and modeling and development of reports with limited supervision.
- Ability to work comfortably in a client environment and communicate and collaborate with peer scientists.
- Developing ability to identify new business development opportunities through client interactions.
- Proficiency in spoken and written English.
- Willingness to travel less than 10 percent.
- Support projects for Certara’s clients by working in teams with Associates, senior expert modelers, and drug development consultants.
- Perform hands-on pharmacometric modeling on client projects as a billable consultant.
- Conduct quality control activities on model code and reports.
- Lead or coordinate company initiatives such as information technology, methodology, efficiency, automation, and quality initiatives when needed.
- Act as the primary point of contact for clients and collaborate with a senior consultant to grow business when needed.
- Solid experience in pharmacometrics, clinical pharmacology, pharmacokinetics, or a related discipline in a project team setting, whether in academia or industry.
- Experience moving compounds through the clinical trials process and experience with elements of clinical development, trial design and management, and filings.
- Additional spoken languages.
Certara provides biosimulation and model-informed drug development tools and services to pharma, CROs, and researchers. Its products include Phoenix WinNonlin for PK/PD and NCA, the Simcyp Simulator for PBPK modeling, D360 for scientific informatics, and Certara.AI for AI-assisted medical writing and regulatory tasks. The platform suite builds and runs mathematical models to predict drug behavior, streamline data, and support regulatory submissions across discovery to market access. It differentiates itself with an end-to-end ecosystem and broad regulatory experience, serving thousands of organizations worldwide to speed up and improve drug development decisions.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Radnor Township, Pennsylvania
Founded
2008
Get referred to Certara
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 software revenue rose 4%, offsetting services weakness and lifting software to 53%.
- August 4 2026 guidance reaffirmed 0%-4% growth and $13 million run-rate savings.
- $150 million buybacks and Julien Perrier's August 2026 sales leadership signal discipline.
What critics are saying
- Q2 2026 revenue grew 1%; services fell 3%, exposing slower nonsoftware demand.
- Divesting Regulatory and Medical Writing removed $50 million 2025 revenue and 220 employees.
- If software bookings stall, Certara becomes a shrinking niche vendor by 2027.
What makes Certara unique
- Certara's Simcyp, Phoenix, and Chemaxon stack spans PK/PD, PBPK, and cheminformatics.
- July 2026 NVIDIA partnership embeds agentic AI into regulated drug-development workflows.
- RsNLME October 2026 brings nonlinear mixed-effects modeling into R with QRPEM stability.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 7%1 year growth
↑ 7%2 year growth
↑ 17%An introduction to fast and reliable modeling with RsNLME and agentic AI. DMDG-GMP-SPS Joint Meeting 2026 workshop - presenter: dr. Bernd wendt (Certara). Date: October 5, 2026 Time: 9:00 AM - 12:00 PM (CET) Location: Diplomat Hotel Prague (DMDG-GMP-SPS Joint Meeting 2026 conference venue), Evropska 15, 160 41 Praha 6 Summary. Population PK/PD modeling is a core skill for today's pharmacometrician, but workflows can be time-consuming, technically demanding, and difficult to scale. RsNLME (R Speaks NLME) addresses this by bringing Certara's powerful NLME engine directly into the R environment, giving modelers the flexibility of open-source R with the reliability of an industry-standard modeling engine, supporting both GUI and command-line workflows and seamlessly integrating with R's tidyverse ecosystem. Its QRPEM estimation algorithm delivers proven numerical stability even for complex, high-dimensional models where other platforms struggle, and because model coding, estimation, diagnostics, and simulation all live within a single R-based ecosystem, there is no need to maintain parallel code across tools. In this hands-on workshop as part of the DMDG-GMP-SPS Joint Meeting 2026, you will get a practical introduction to population PK/PD modeling with RsNLME, from exploratory data analysis through covariate modeling, goodness of fit diagnostics, and VPC generation. As a special highlight, Certara will also give you a first look at something new: an agentic AI workflow built on top of RsNLME. Powered by an MCP (Model Context Protocol) server bundled directly into RsNLME, this capability allows AI agents such as Cursor or Claude to execute full pharmacometric workflows end to end, from EDA to model selection to final diagnostics, simply by describing what you want to do in plain language. Join Certara for breakfast, a hands-on session, and a glimpse into where pharmacometric modeling is heading. What you will learn: * Core concepts and workflow of population PK/PD modeling with RsNLME * How RsNLME integrates with the R ecosystem for flexible, reproducible analyses * How agentic AI can automate and accelerate your modeling workflows using RsNLME's MCP server From first-in-human trials to global regulatory approvals and post-launch, Certara solutions can help you move your science forward faster, with confidence.
Certara has reaffirmed full-year revenue guidance of 0% to 4% growth, with software expected to perform at the high end while services may lag. The company reported software revenue now represents 53% of business, up from 40% two years ago, reflecting a strategic shift toward more scalable products. The biosimulation software firm executed a 5% global workforce reduction to eliminate stranded costs from its recent regulatory and medical writing business divestiture. Management expects £13 million in run-rate savings from operational excellence initiatives to support future margin expansion. Certara authorised a new $50 million share repurchase programme after completing a previous $100 million programme. The company reported a net loss from continuing operations of $6.1 million, primarily due to currency headwinds and the absence of a prior-year adjustment.
Certara reported Q2 2026 revenue of $93.3 million, up 1% year-over-year, driven by 4% software growth that offset a 3% decline in services. Software now accounts for 53% of the business. The company reaffirmed its 2026 revenue guidance of $367 million to $382 million but lowered its adjusted EBITDA margin forecast to 29-31% from 30-32%, citing divestiture-related costs and business-mix changes. Software bookings increased 9% to $50.7 million, with trailing 12-month software bookings rising 8% to $196.4 million. Certara is implementing operational changes including workforce reductions expected to deliver approximately $13 million in annualized savings. The company completed a $100 million share repurchase programme and authorised an additional $50 million.
Certara reported second quarter 2026 revenue of $93.3 million, up 1% from $92.4 million in the same period last year. The model-informed drug development company's software revenue grew 4% to $48.8 million, while services revenue declined 3% to $44.5 million. The company posted a net loss of $6.1 million, compared to net income of $1.5 million in Q2 2025. The shift primarily reflected the absence of a favourable contingent consideration adjustment from the prior year, increased currency expenses, and higher reorganisation costs. Certara completed its previously authorised $100 million share repurchase programme and received board approval for an additional $50 million buyback. The company appointed Julien Perrier as Chief Commercial Officer and reaffirmed its 2026 revenue guidance of 0% to 4% growth.
Certara (CERT) to announce earnings on Tuesday. July 28, 2026 Key points. * Certara is expected to report Q2 2026 results before the market opens Tuesday, August 4. Analysts anticipate earnings of $0.10 per share on revenue of approximately $98.1 million; full-year EPS guidance is $0.350-$0.410. * In its prior quarter, Certara reported EPS of $0.09, missing estimates of $0.11, while revenue of $106.92 million exceeded expectations and rose 0.8% year over year. * Shares recently rose 5.2% to $8.15, but Wall Street maintains a consensus "Hold" rating with an $8.85 price target. Institutional investors own approximately 74% of the stock. * Five stocks to consider instead of Certara. Certara (NASDAQ:CERT - Get Free Report) is expected to be releasing its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to announce earnings of $0.10 per share and revenue of $98.0870 million for the quarter. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Interested persons can find conference call details on the company's upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:30 AM ET. Certara (NASDAQ:CERT - Get Free Report) last announced its earnings results on Monday, May 11th. The company reported $0.09 earnings per share for the quarter, missing analysts' consensus estimates of $0.11 by ($0.02). The company had revenue of $106.92 million during the quarter, compared to analyst estimates of $106.13 million. Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.Certara's revenue for the quarter was up .8% on a year-over-year basis. During the same period in the previous year, the company posted $0.14 earnings per share. On average, analysts expect Certara to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year. Certara stock up 5.2%. CERT stock traded up $0.40 during trading hours on Tuesday, reaching $8.15. 1,096,341 shares of the stock were exchanged, compared to its average volume of 3,657,619. The firm's 50-day moving average is $6.06 and its 200-day moving average is $6.62. Certara has a 12 month low of $4.45 and a 12 month high of $13.88. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -81.58 and a beta of 1.46. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 1.88. Wall Street analysts forecast growth. Several research firms have recently weighed in on CERT. BMO Capital Markets reduced their price objective on Certara from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Tuesday, May 12th. Craig Hallum dropped their target price on Certara from $10.00 to $8.00 and set a "hold" rating on the stock in a research report on Tuesday, May 12th. Stephens cut their target price on Certara from $10.00 to $9.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 12th. Morgan Stanley reduced their price target on Certara from $11.00 to $10.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 12th. Finally, Robert W. Baird decreased their price target on shares of Certara from $7.00 to $6.00 and set a "neutral" rating for the company in a research note on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $8.85. Discover more Dividend Screener Tool Hedge funds weigh in on Certara. A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Corient Private Wealth LLC acquired a new position in shares of Certara in the fourth quarter valued at approximately $100,000. T. Rowe Price Investment Management Inc. lifted its holdings in Certara by 580,097.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 829,683 shares of the company's stock worth $7,310,000 after purchasing an additional 829,540 shares during the last quarter. nVerses Capital LLC acquired a new stake in Certara during the 4th quarter worth approximately $184,000. Toronto Dominion Bank boosted its stake in Certara by 186.9% in the 4th quarter. Toronto Dominion Bank now owns 83,939 shares of the company's stock valued at $739,000 after purchasing an additional 54,677 shares during the period. Finally, Oxford Asset Management LLP bought a new stake in Certara in the 4th quarter valued at $256,000. 73.96% of the stock is owned by institutional investors. Certara company profile. Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company's platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle. The company's offerings are divided into software tools and consulting services. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Certara, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Certara wasn't on the list. While Certara currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.